Загрузка...
Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis
Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type 2 diabetes mellitus. By inhibiting enzymatic decomposition, DPP-4 inhibitors increase the half-life of incretins such as GLP-1 (Gluc...
Сохранить в:
| Главные авторы: | , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
MDPI AG
2020-03-01
|
| Серии: | International Journal of Molecular Sciences |
| Предметы: | |
| Online-ссылка: | https://www.mdpi.com/1422-0067/21/7/2275 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|